CASI Pharmaceuticals (FRA:ENM) Other Operating Expense : €-5.84 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Other Operating Expense?

CASI Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-5.84 Mil.

CASI Pharmaceuticals's quarterly Other Operating Expense declined from Sep. 2023 (€-0.00 Mil) to Dec. 2023 (€-5.84 Mil) but then increased from Dec. 2023 (€-5.84 Mil) to Mar. 2024 (€0.00 Mil).

CASI Pharmaceuticals's annual Other Operating Expense declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) and declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€-5.84 Mil).

CASI Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for CASI Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Other Operating Expense Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-5.84

CASI Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-5.84	-

CASI Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.84 Mil.

CASI Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines